“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Correlations Between Patient-Reported Outcomes and Clinical Responses in the Phase 3 Clinical Trials POETYK PSO-1 and POETYK PSO-2”. SKIN The Journal of Cutaneous Medicine 6, no. 6 (November 16, 2022): s63. Accessed April 17, 2026. https://skin.dermsquared.com/skin/article/view/1818.